info@birdgroup.be

Login

Papers

Gastroenterology . 2026 Feb 24:S0016-5085(26)00146-0. doi: 10.1053/j.gastro.2026.01.042. Online ahead of print.
The effect of dose-intensification after secondary loss of response to ustekinumab in Crohn's disease: Results of the REScUE study

Journal of Crohn's and Colitis, jjad179, Epub: 02 November 2023
Early versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological Outcomes

Eur J Cancer . 2023 Jul;187:36-57. doi: 10.1016/j.ejca.2023.03.025. Epub 2023 Mar 25.
Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus

Journal of Crohn's and Colitis, 27 September 2022, jjac145
What are the Unmet Needs and Most Relevant Treatment Outcomes According to Patients with Infammatory Bowel Disease? A Qualitative Patient Preference Study

Gastroenterology. 2022 Aug 5;S0016-5085(22)00828-9
Effect of 5-hydroxytryptophan on fatigue in quiescent inflammatory bowel disease: a randomized controlled trial

Inflamm Bowel Dis . 2022 Jan 15;izab339.
The Multiple Waves of COVID-19 in Patients With Inflammatory Bowel Disease: A Temporal Trend Analysis

Journal of Crohn's and Colitis, jjac009, 25 january 2022
Introduction of subcutaneous infliximab CT-P13 and vedolizumab in clinical practice: a multi-stakeholder position statement highlighting the need for post-marketing studies

DIAMOND Platform from the Belgian IBD Research; Development (BIRD) group

Gastroenterology 2019;157(4): 997-1006.e6. Epub 2019 Jun 5.
Vedolizumab Induces Endoscopic and Histologic Remission in Patients with Crohn's Disease.

1
2
3
4
5
6
7
›